Given that this microRNA is frequently studied for its oncogenic role in the PI3K-Akt pathway across various cancers, it can be concluded that, within our heterogeneous cohort, the expression levels of this microRNA do not change following COVID-19 vaccination. This evidence concerns the gene AKT1 and cancer.